ProQR Therapeutics NV (NASDAQ:PRQR) has earned an average rating of “Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $19.13.
Several brokerages recently commented on PRQR. ValuEngine raised shares of ProQR Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 23rd. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Wednesday, April 18th. Finally, Chardan Capital began coverage on shares of ProQR Therapeutics in a research report on Thursday, April 5th. They set a “buy” rating and a $4.50 price target for the company.
Hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in ProQR Therapeutics by 519.0% during the first quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 28,025 shares during the last quarter. Sabby Management LLC acquired a new position in ProQR Therapeutics during the fourth quarter worth approximately $1,120,000. Sphera Funds Management LTD. increased its position in ProQR Therapeutics by 24.2% during the first quarter. Sphera Funds Management LTD. now owns 658,500 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 128,500 shares during the last quarter. Finally, Artal Group S.A. increased its position in shares of ProQR Therapeutics by 26.7% in the fourth quarter. Artal Group S.A. now owns 1,900,000 shares of the biopharmaceutical company’s stock worth $6,128,000 after acquiring an additional 400,000 shares in the last quarter. 33.55% of the stock is owned by hedge funds and other institutional investors.
ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Wednesday, May 16th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.06. equities analysts forecast that ProQR Therapeutics will post -1.53 EPS for the current fiscal year.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.